News
GHRS
29.08
-1.52%
-0.45
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Elanco Animal Health (ELAN)
TipRanks · 1d ago
Weekly Report: what happened at GHRS last week (0803-0807)?
Weekly Report · 2d ago
RBC Capital Remains a Buy on GH Research (GHRS)
TipRanks · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)
TipRanks · 4d ago
GH Research Is Maintained at Buy by Guggenheim
Dow Jones · 4d ago
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Benzinga · 4d ago
GH Research Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 5d ago
GH Research Price Target Raised to $40.00/Share From $35.00 by Cantor Fitzgerald
Dow Jones · 5d ago
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Benzinga · 5d ago
GH Research price target raised to $40 from $34 at Guggenheim
TipRanks · 5d ago
GH Research Earns Buy Rating on FDA Phase 3 Green Light, Strong TRD Strategy and Solid Cash Runway
TipRanks · 5d ago
GH Research Is Maintained at Buy by Needham
Dow Jones · 5d ago
Needham Maintains Buy on GH Research, Raises Price Target to $39
Benzinga · 5d ago
GH Research price target raised to $39 from $32 at Needham
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)
TipRanks · 5d ago
Psychedelic: Compass Pathways, GH Research report quarterly earnings
TipRanks · 5d ago
GH Research reports Q2 EPS (23c), consensus (30c)
TipRanks · 6d ago
GH Research GAAP EPS of -$0.23
Seeking Alpha · 6d ago
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
Benzinga · 6d ago
Weekly Report: what happened at GHRS last week (0727-0731)?
Weekly Report · 08/03 09:20
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.